Effect of a selective and potent central nervous system penetrant, neurokinin-3 receptor antagonist (SB-222200), on cisplatin-induced emesis in the ferret

Neuroscience Letters

Volumn 376, Issue 1, 2005, Pages 5-8

  King, Andrew G ^a   Sanger, Gareth J ^b  

^a GLAXOSMITHKLINE   (United States)

^b Neurol Gastroenterol Ctr E   (United Kingdom)

Author keywords

Cisplatin; Emesis; Ferret; Neurokinin; NK 3; Ondansetron; SB 222200

Indexed keywords

CISPLATIN; N (ALPHA ETHYLBENZYL) 3 METHYL 2 PHENYL 4 QUINOLINECARBOXAMIDE; NEUROKININ 3 RECEPTOR; NEUROKININ 3 RECEPTOR ANTAGONIST; ONDANSETRON; SEROTONIN 3 ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIEMETIC ACTIVITY; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRINKING BEHAVIOR; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; EVOKED RESPONSE; FEEDING BEHAVIOR; FERRET; MALE; NAUSEA; NONHUMAN; PRIORITY JOURNAL; VOMITING;

EID: 13444283733     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2004.11.015     Document Type: Article

References (18)

1. R.V. Alves, M.M. Campos, A.R. Santos, and J.B. Calixto Receptor subtypes involved in tachykinin-mediated edema formation Peptides 20 1999 921 927
2. J. Bermudez, E.A. Boyle, W.D. Miner, and G.J. Sanger The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694 Br. J. Cancer. 58 1988 644 650
3. C. Blondeau, N. Clerc, and A. Baude Neurokinin-1 and neurokinin-3 receptors are expressed in vagal efferent neurons that innervate different parts of the gastro-intestinal tract Neuroscience 110 2002 339 349
4. C. Carpentier, and A. Baude Immunocytochemical localisation of NK3 receptors in the dorsal vagal complex of rat Brain Res. 734 1996 327 331
5. V. Cocquyt, S. Van Belle, R.R. Reinhardt, M.L. Decramer, M. O'Brien, J.H. Schellens, M. Borms, L. Verbeke, F. Van Aelst, M. De Smet, A.D. Carides, K. Eldridge, and B.J. Gertz Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis Eur. J. Cancer. 37 2001 835 842
6. J. Fioramonti, E. Gaultier, M. Toulouse, G.J. Sanger, and L. Bueno Intestinal anti-nociceptive behaviour of NK3 receptor antagonism in conscious rats: evidence to support a peripheral mechanism of action Neurogastroenterol. Motil. 15 2003 363 369.
7. C.J. Gardner, D.R. Armour, D.T. Beattie, J.D. Gale, A.B. Hawcock, G.J. Kilpatrick, D.J. Twissell, and P. Ward GR205171: a novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity Regul. Pept. 65 1996 45 53
8. P.J. Hesketh, S. Van Belle, M. Aapro, F.D. Tattersall, R.J. Naylor, R. Hargreaves, A.D. Carides, J.K. Evans, and K.J. Horgan Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists Eur. J. Cancer. 39 2003 1074 1080
9. G.L. King Animal models in the study of vomiting Can. J. Physiol. Pharmacol. 68 1990 260 268
10. C.A. Maggi The mammalian tachykinin receptors Gen. Pharmacol. 26 1995 911 944
11. D. Mileusnic, J.M. Lee, D.J. Magnuson, M.J. Hejna, J.E. Krause, J.B. Lorens, and S.A. Lorens Neurokinin-3 receptor distribution in rat and human brain: an immunohistochemical study Neuroscience 89 1999 1269 1290
12. J.A. Rudd, K.T. Bunce, and R.J. Naylor The interaction of dexamethasone with ondansetron on drug-induced emesis in the ferret Neuropharmacology 35 1996 91 97
13. J.A. Rudd, C.C. Jordan, and R.J. Naylor The action of the NK1 tachykinin receptor antagonist, CP 99,994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret Br. J. Pharmacol. 119 1996 931 936
14. J.A. Rudd, and R.J. Naylor The actions of ondansetron and dexamethasone to antagonise cisplatin-induced emesis in the ferret Eur. J. Pharmacol. 322 1997 79 82
15. H.M. Sarau, D.E. Griswold, B. Bush, W. Potts, P. Sandhu, D. Lundberg, J.J. Foley, D.B. Schmidt, E.F. Webb, L.D. Martin, J.J. Legos, R.G. Whitmore, F.C. Barone, A.D. Medhurst, M.A. Luttmann, G.A. Giardina, and D.W. Hay Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist J. Pharmacol. Exp. Ther. 295 2000 373 381
16. A.D. Shafton, G. Bogeski, P.D. Kitchener, V.A. Lewis, G.J. Sanger, and J.B. Furness Effects of the peripherally acting NK receptor antagonist, SB-235375, on intestinal and somatic nociceptive responses and on intestinal motility in anaesthetized rats Neurogastroenterol. Motil. 16 2004 223 231
17. F.D. Tattersall, W. Rycroft, M. Cumberbatch, G. Mason, S. Tye, D.J. Williamson, J.J. Hale, S.G. Mills, P.E. Finke, M. MacCoss, S. Sadowski, E. Ber, M. Cascieri, R.G. Hill, D.E. MacIntyre, and R.J. Hargreaves The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets Neuropharmacology 39 2000 652 663
18. J.W. Watson, S.F. Gonsalves, A.A. Fossa, S. McLean, T. Seeger, S. Obach, and P.L. Andrews The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor Br. J. Pharmacol. 115 1995 84 94